Cargando…
Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent Mechanism
Insulin resistance and diabetes are both associated with chronic hepatitis C virus (HCV) infection, and the glucagon-like peptide-1(GLP-1) receptor agonist, liraglutide, is a common therapy for diabetes. Our aim was to investigate whether liraglutide treatment can inhibit HCV replication. A cell cul...
Autores principales: | Lee, Mei-Yueh, Chen, Wei-Chun, Hsu, Wei-Hao, Chen, Szu-Chia, Lee, Jin-Ching |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769880/ https://www.ncbi.nlm.nih.gov/pubmed/31540136 http://dx.doi.org/10.3390/ijms20184569 |
Ejemplares similares
-
Bromelain activates the AMP-activated protein kinase-autophagy pathway to alleviate hepatic lipid accumulation
por: Hu, Po-An, et al.
Publicado: (2022) -
Nobiletin Inhibits Hepatic Lipogenesis via Activation of AMP-Activated Protein Kinase
por: Yuk, Taewon, et al.
Publicado: (2018) -
Liraglutide suppresses the proliferation of endometrial cancer cells through the adenosine 5′-monophosphate (AMP)-activated protein kinase signaling pathway
por: Zhu, Xin-Xin, et al.
Publicado: (2021) -
Common Risk Factors in Relatives and Spouses of Patients with Type 2 Diabetes in Developing Prediabetes
por: Hsu, Wei-Hao, et al.
Publicado: (2021) -
Liraglutide inhibits the progression of prediabetes in rats by reducing Raf-1 kinase inhibitor protein
por: Gao, Fei, et al.
Publicado: (2021)